Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial, which showed best overall and complete response rates of 91% and 68%, respectively. We report clinical outcomes with brexu-cel in the standard-of-care setting for the approved indication. PATIENTS AND METHODS Patients who underwent leukapheresis between August 1, 2020 and December 31, 2021, at 16 US institutions, with an intent to manufacture commercial brexu-cel for relapsed/refractory MCL, were included. Patient data were collected for analyses of…

• CC
  Conquer Cancer Foundation
• A
  Amgen
• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• GS
  Gilead Sciences
• AS
  American Society of Clinical Oncology
• C
  Celgene
• VU
  Vanderbilt University
• UO
  University of Miami
• WS
  Wayne State University
• KT
  Karyopharm Therapeutics
• WU
  Washington University in St. Louis
• CC
  Cleveland Clinic
• UO
  University of Kansas
• MC
  Moffitt Cancer Center

  Awards: P30 CA076292, CA076292
• TT
  TG Therapeutics
• BB
  bluebird bio
• AB
  Adaptive Biotechnologies
• I
  Incyte
• AS
  Alimera Sciences
• M
  MorphoSys
• G
  Genentech
• UO
  University of Texas MD Anderson Cancer Center
• LB
  Legend Biotech
• NC
  National Cancer Institute

  Awards: CA076292, P30 CA076292, K12CA167540
• DS
  Daiichi Sankyo Europe